-
公开(公告)号：US20050079151A1
公开(公告)日：2005-04-14
申请号：US10641728
申请日：2003-08-15
申请人： Shinya Ikematsu , Yoshihiro Yoshida , Kenji Kadomatsu , Munehiro Oda , Sadatoshi Sakuma , Kin-ya Ashida , Kohsuke Kino , Takashi Muramatsu
发明人： Shinya Ikematsu , Yoshihiro Yoshida , Kenji Kadomatsu , Munehiro Oda , Sadatoshi Sakuma , Kin-ya Ashida , Kohsuke Kino , Takashi Muramatsu
CPC分类号： A61K38/18
摘要： Proteins belonging to the MK family can suppress apoptosis induced by various stimuli such as carcinostatics, ultraviolet light and radiation, ischemic stresses, etc. Based on this finding, the invention provides novel agents for treating or preventing various diseases attributed to apoptosis such as cerebropathy, cardiopathy, nephropathy, neuropathy, or hepatopathy, etc., comprising proteins belonging to the MK family as an effective ingredient.
摘要翻译： 属于MK家族的蛋白质可以抑制由诸如制癌学，紫外光和辐射，缺血应激等各种刺激物诱导的凋亡。基于这一发现，本发明提供了用于治疗或预防由细胞凋亡引起的各种疾病如脑病， 心脏病，肾病，神经病或肝病等，其包含属于MK家族的蛋白质作为有效成分。
-
公开(公告)号：US06572851B2
公开(公告)日：2003-06-03
申请号：US09380882
申请日：1999-12-02
IPC分类号： A61K3800
CPC分类号： A61K38/18
摘要： The present invention provides a novel drug for relieving drug-induced nephropathy and acute hepatopahy containing a midkine (MK) family protein such as pleiotrophin (PTN). The MK family proteins can inhibit nephropathy induced by an antitumor agent or acute hepatopathy caused by carbon tetrachloride and thus effectively relieve drug-induced nephropathy or hepatopathy.
摘要翻译： 本发明提供了一种用于缓解药物诱导的肾病和含有中期因子（MK）家族蛋白如多效素（PTN）的急性肝细胞的新型药物。 MK家族蛋白可以抑制由四氯化碳引起的抗肿瘤剂或急性肝病引起的肾病，从而有效缓解药物诱发的肾病或肝病。
-
3.发明授权Pharmaceutical compositions for the prevention and treatment of atherosclerosis and restenosis after PTCA 有权用于预防和治疗PTCA后的动脉粥样硬化和再狭窄的药物组合物公开(公告)号：US07309695B2
公开(公告)日：2007-12-18
申请号：US10703783
申请日：2003-11-06
CPC分类号： C12N15/1136 , A61K2039/505 , C07K14/475 , C07K16/22 , C12N15/1137 , C12N15/1138
摘要： The present invention provides a pharmaceutical composition for the prevention or treatment of angiostenosis, comprising a compound inhibiting the function of midkine (MK) in blood vessel tissues as an effective ingredient. The present invention is useful for the prevention or treatment of angiostenosis attributed to arteriosclerosis or restenosis after percutaneous transluminal coronary angioplasty (PTCA). As compounds inhibiting the function of MK, antisense oligonucleotides that bind to a segment of a single-stranded mRNA transcribed from the MK gene to inhibit the synthesis of MK protein in cells, antibodies against the MK protein, and such can be used.
摘要翻译： 本发明提供了一种用于预防或治疗血管狭窄症的药物组合物，其包含抑制血管组织中的中期因子（MK）作为有效成分的功能的化合物。 本发明可用于预防或治疗经皮腔内冠状动脉血管成形术（PTCA）后动脉硬化或再狭窄引起的血管狭窄。 作为抑制MK功能的化合物，可以使用结合从MK基因转录的单链mRNA片段抑制细胞中MK蛋白合成的抗体的反义寡核苷酸等。
-
公开(公告)号：US07090983B1
公开(公告)日：2006-08-15
申请号：US10070569
申请日：2000-09-08
申请人： Takashi Muramatsu , Kohji Okamoto , Shinya Ikematsu , Munehiro Oda , Hideshi Kumai , Sadatoshi Sakuma
发明人： Takashi Muramatsu , Kohji Okamoto , Shinya Ikematsu , Munehiro Oda , Hideshi Kumai , Sadatoshi Sakuma
IPC分类号： G01N33/53 , G01N33/567 , G01N33/574 , G01N33/543 , C12Q1/00
CPC分类号： G01N33/57484 , G01N33/574 , G01N2333/475
摘要： MK (midkine) was found to rise in the blood or urine of patients with various types of cancers at early stage. Based on this finding, a method for detecting early cancer, comprising the step of measuring MK in blood or urine was completed.
摘要翻译： MK（midkine）在早期发现患有各种类型癌症的患者的血液或尿液中升高。 基于这一发现，完成了检测早期癌症的方法，包括测量血液或尿液中的MK的步骤。
-
5.发明申请Pharmaceutical Compositions for the Prevention and Treatment of Atherosclerosis and Restenosis After PTCA 有权用于预防和治疗PTCA后的动脉粥样硬化和再狭窄的药物组合物公开(公告)号：US20080107659A1
公开(公告)日：2008-05-08
申请号：US11936438
申请日：2007-11-07
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： C12N15/1136 , A61K2039/505 , C07K14/475 , C07K16/22 , C12N15/1137 , C12N15/1138
摘要： The present invention provides a pharmaceutical composition for the prevention or treatment of angiostenosis, comprising a compound inhibiting the function of midkine (MK) in blood vessel tissues as an effective ingredient. The present invention is useful for the prevention or treatment of angiostenosis attributed to arteriosclerosis or restenosis after percutaneous transluminal coronary angioplasty (PTCA). As compounds inhibiting the function of MK, antisense oligonucleotides that bind to a segment of a single-stranded mRNA transcribed from the MK gene to inhibit the synthesis of MK protein in cells, antibodies against the MK protein, and such can be used.
摘要翻译： 本发明提供了一种用于预防或治疗血管狭窄症的药物组合物，其包含抑制血管组织中的中期因子（MK）作为有效成分的功能的化合物。 本发明可用于预防或治疗经皮腔内冠状动脉血管成形术（PTCA）后动脉硬化或再狭窄引起的血管狭窄。 作为抑制MK功能的化合物，可以使用结合从MK基因转录的单链mRNA片段抑制细胞中MK蛋白合成的抗体的反义寡核苷酸等。
-
公开(公告)号：US07820160B2
公开(公告)日：2010-10-26
申请号：US11936438
申请日：2007-11-07
IPC分类号： A61K39/395 , A61K48/00
CPC分类号： C12N15/1136 , A61K2039/505 , C07K14/475 , C07K16/22 , C12N15/1137 , C12N15/1138
摘要： The present invention provides a pharmaceutical composition for the prevention or treatment of angiostenosis, comprising a compound inhibiting the function of midkine (MK) in blood vessel tissues as an effective ingredient. The present invention is useful for the prevention or treatment of angiostenosis attributed to arteriosclerosis or restenosis after percutaneous transluminal coronary angioplasty (PTCA). As compounds inhibiting the function of MK, antisense oligonucleotides that bind to a segment of a single-stranded mRNA transcribed from the MK gene to inhibit the synthesis of MK protein in cells, antibodies against the MK protein, and such can be used.
摘要翻译： 本发明提供了一种用于预防或治疗血管狭窄症的药物组合物，其包含抑制血管组织中的中期因子（MK）作为有效成分的功能的化合物。 本发明可用于预防或治疗经皮腔内冠状动脉血管成形术（PTCA）后动脉硬化或再狭窄引起的血管狭窄。 作为抑制MK功能的化合物，可以使用结合从MK基因转录的单链mRNA片段抑制细胞中MK蛋白合成的抗体的反义寡核苷酸等。
-
公开(公告)号：US06939669B2
公开(公告)日：2005-09-06
申请号：US10071039
申请日：2002-02-08
IPC分类号： A61K35/28 , A61K38/18 , A61K38/19 , A61K38/20 , C12N5/0789 , C12N5/00 , C07K14/475 , C07K14/52
CPC分类号： C12N5/0647 , A61K35/28 , A61K38/18 , A61K38/193 , C12N2500/25 , C12N2501/10 , C12N2501/125 , C12N2501/14 , C12N2501/22 , C12N2501/23 , Y10S514/885 , A61K2300/00
摘要： The present invention provides novel use of the MK family that is used alone as an agent for proliferating hematopoietic stem cells and hematopoietic precursor cells. The invention also provides an agent for remarkably enhancing the above-described effect for promoting the proliferation of hematopoietic stem cells and hematopoietic precursor cells, comprising the MK family in combination with known hematopoietic factors such as IL-3, IL-6, G-CSF, GM-CSF, M-CSF, SCF, and EPO.
摘要翻译： 本发明提供了单独使用作为增殖造血干细胞和造血前体细胞的药剂的MK家族的新用途。 本发明还提供了用于显着增强上述促进造血干细胞和造血前体细胞增殖的作用的药剂，其包含MK家族与已知造血因子如IL-3，IL-6，G-CSF的组合 ，GM-CSF，M-CSF，SCF和EPO。
-
公开(公告)号：US6083907A
公开(公告)日：2000-07-04
申请号：US12084
申请日：1998-01-22
申请人： Masayuki Uchida , Shinya Ikematsu , Minehiko Yokoyama , Akio Yamashita , Hideshi Kumai , Munehiro Oda , Naoki Kato , Sadatoshi Sakuma , Takashi Muramatsu
发明人： Masayuki Uchida , Shinya Ikematsu , Minehiko Yokoyama , Akio Yamashita , Hideshi Kumai , Munehiro Oda , Naoki Kato , Sadatoshi Sakuma , Takashi Muramatsu
CPC分类号： A61K38/18 , A61K31/4164 , A61K31/727 , A61K45/06
摘要： An anti-ulcer composition is provided, which comprises as an active ingredient at least one of MK protein, its derivative having biological activity of MK protein, and their fragment having biological activity of MK protein, and a pharmaceutically acceptable carrier. The composition exhibits an effect for treating ulcer by promoting autotherapy without recurrence of ulcer.
摘要翻译： 提供了一种抗溃疡组合物，其包含作为活性成分的至少一种MK蛋白，其具有MK蛋白生物活性的衍生物及其具有MK蛋白生物活性的片段和药学上可接受的载体。 该组合物通过促进自体治疗而不复发溃疡具有治疗溃疡的作用。
-
9.发明授权Composition comprising midkine or pleiotrophin protein and method of increasing hematopoietic cells 有权包含中期因子或多余肌营养蛋白的组合物和增加造血细胞的方法公开(公告)号：US06383480B1
公开(公告)日：2002-05-07
申请号：US09214569
申请日：1999-01-07
IPC分类号： A61K3800
CPC分类号： C12N5/0647 , A61K35/28 , A61K38/18 , A61K38/193 , C12N2500/25 , C12N2501/10 , C12N2501/125 , C12N2501/14 , C12N2501/22 , C12N2501/23 , Y10S514/885 , A61K2300/00
摘要： The present invention provides novel use of the MK family that is used alone as an agent for proliferating hematopoietic stem cells and hematopoietic precursor cells. The invention also provides an agent for remarkably enhancing the above-described effect for promoting the proliferation of hematopoietic stem cells and hematopoietic precursor cells, comprising the MK family in combination with known hematopoietic factors such as IL-3, IL-6, G-CSF, GM-CSF, M-CSF, SCF, and EPO.
摘要翻译： 本发明提供了单独使用作为增殖造血干细胞和造血前体细胞的药剂的MK家族的新用途。 本发明还提供了用于显着增强上述促进造血干细胞和造血前体细胞增殖的作用的药剂，其包含MK家族与已知造血因子如IL-3，IL-6，G-CSF的组合 ，GM-CSF，M-CSF，SCF和EPO。
-
10.发明授权公开(公告)号：US08106009B2
公开(公告)日：2012-01-31
申请号：US10371030
申请日：2003-02-21
IPC分类号： A61K38/18 , C07K14/475
CPC分类号： A61K38/18 , A61K38/1825 , A61K38/185 , A61K38/204 , A61K2300/00
摘要： A pharmaceutical composition for treating or preventing cytopathy caused by ischemia, comprising a midkine family protein as an active ingredient, and a pharmaceutical composition for treating or preventing ischemic disorders, comprising a midkine family protein as an active ingredient, are provided. Midkine is efficacious in treating or preventing ischemic disorders and cytopathy caused by ischemia and can remarkably prevent, for example, the development of cerebral infarction, a representative of ischemic brain disorders. The pharmaceutical composition of the present invention is also efficacious against, for example, cerebral ischemic disorders such as cerebrovascular-spasm following a subarachnoid hemorrhage, Alzheimer's disease, senile dementia of Alzheimer's type, and cerebrovascular senile dementia, as well as cerebral ischemia, transient cerebral ischemic disease, and head trauma, and other cerebrovascular diseases such as Parkinson's disease, Huntington's chorea, and amyotrophic regressive disorders.
摘要翻译： 提供了用于治疗或预防由缺血引起的细胞病变的药物组合物，其包含中期因子家族蛋白作为活性成分，以及用于治疗或预防缺血性疾病的药物组合物，其包含中期因子家族蛋白作为活性成分。 Midkine有效治疗或预防局部缺血引起的缺血性疾病和细胞病变，并且可以显着地预防例如缺血性脑病的代表性脑梗塞的发展。 本发明的药物组合物对于例如脑缺血障碍如蛛网膜下腔出血后的脑血管痉挛，阿尔茨海默氏病，老年痴呆型老年痴呆，脑血管性老年性痴呆，以及脑缺血，暂时性大脑 缺血性疾病和头部创伤，以及其他脑血管疾病如帕金森病，亨廷顿氏舞蹈病和肌萎缩性退行性疾病。
-
-
-
-
-
-
-
-
-
搜索结果
22 条记录 (耗时 0.036 秒)
